Compare CALX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | NUVB |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.9B |
| IPO Year | 2009 | N/A |
| Metric | CALX | NUVB |
|---|---|---|
| Price | $50.52 | $4.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $74.75 | $11.22 |
| AVG Volume (30 Days) | 1.1M | ★ 4.8M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $510,367,000.00 | N/A |
| Revenue This Year | $16.40 | $182.76 |
| Revenue Next Year | $13.75 | $91.83 |
| P/E Ratio | $200.15 | ★ N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $28.61 | $1.57 |
| 52 Week High | $71.22 | $9.75 |
| Indicator | CALX | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 33.85 |
| Support Level | $45.38 | $3.92 |
| Resistance Level | $56.17 | $5.73 |
| Average True Range (ATR) | 2.45 | 0.35 |
| MACD | -0.13 | -0.07 |
| Stochastic Oscillator | 1.53 | 25.27 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.